SPDR S&P Biotech ETF (XBI)
85.43
-3.28 (-3.70%)
At close: Mar 03, 2025, 3:59 PM
85.60
0.20%
After-hours: Mar 03, 2025, 08:00 PM EST
No 1D chart data available
| Bid | 85.31 |
| Market Cap | 5.97B |
| AUM | 7.34B |
| NAV | 99.29 |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Shares Out | 69.89M |
| Inception Date | Jan 31, 2006 |
| Ask | 85.95 |
| Volume | 8.54M |
| Open | 88.74 |
| Previous Close | 88.71 |
| Day's Range | 85.13 - 89.34 |
| 52-Week Range | 81.14 - 105.47 |
| Holdings | 145 |
| Expense Ratio | 0.35% |
About XBI
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
Asset Class Equity
Ticker Symbol XBI
Inception Date Jan 31, 2006
Provider State Street
Website Fund Home Page
Top 10 Holdings 26.35% of assets
| Name | Symbol | Weight |
|---|---|---|
| Gilead Sciences, Inc... | 3.12% | |
| Abbvie Inc. | 3.02% | |
| Amgen Inc. | 2.82% | |
| Biomarin Pharmaceuti... | 2.69% | |
| Insmed Incorporated | 2.63% | |
| Vertex Pharmaceutica... | 2.61% | |
| Incyte Corporation | 2.44% | |
| Alnylam Pharmaceutic... | 2.39% | |
| Halozyme Therapeutic... | 2.37% | |
| Neurocrine Bioscienc... | 2.26% |
Dividends Dividend Yield 0.14%
| Ex-Dividend | Amount | Payment Date |
|---|---|---|
| Dec 23, 2024 | $0.0027 | Dec 26, 2024 |
| Sep 23, 2024 | $0.0152 | Sep 25, 2024 |
| Jun 24, 2024 | $0.1148 | Jun 26, 2024 |
| Dec 18, 2023 | $0.0139 | Dec 21, 2023 |
| Jun 20, 2023 | $0.0026 | Jun 23, 2023 |
